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Structured Abstract 
 
Introduction 
Poor adherence in children with asthma is a major cause of asthma attacks and poor control, leads to 
large healthcare costs and has been identified as a factor in asthma deaths.  However, it is difficult to 
detect and frequently overlooked leading to inappropriate escalation of asthma treatment. There is a 
need for cost effective ways to monitor adherence in order to intervene to change this modifiable 
behaviour.  
Areas Covered 
Several measurement tools have been developed to assess adherence in adults and children with 
asthma. The current methods for measuring adherence, both subjective and objective, have several 
flaws and even the current gold standard, electronic monitoring devices (EMDs), has limitations. This 
review will outline and critique the adherence monitoring tools and highlight ways in which they have 
been used for the purpose of intervention. 
Expert Review 
Although advances have been made in adherence monitoring we still have some way to go in creating 
the ideal monitoring tool. There are no validated tailored self-monitoring questionnaires for children 
with asthma and most objective measures, such as prescription refill rate and weighing canisters, over-
estimate adherence. Current electronic monitoring devices, although useful, need improved accuracy 
to ensure that both actuation and inhalation are measured, and the devices need to be affordable for 
use in routine health care practice.  
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1. Introduction 
Currently 1.1 million children in the United Kingdom (UK) are diagnosed with asthma (1).  Most 
children with asthma achieve good disease control with low dose inhaled corticosteroids (ICS), yet 
some remain poorly controlled despite high intensity treatment. Tragically a significant number of 
asthma deaths are in young people under the age of 20 (2) and mortality rates for young people in the 
UK are among the highest in Europe (3). The National Review of Asthma Deaths (NRAD) found that 
67% of asthma deaths were avoidable; the most important modifiable factor being patients not taking 
their prescribed asthma medication in the month and/or year before their death (2).  
 
Medication adherence has been shown to be a problem in several long-term conditions in both adults 
(diabetes; schizophrenia; heart disease; asthma) and children (HIV, diabetes, juvenile arthritis and 
asthma) (4). Good adherence in asthma is most commonly defined as taking between 70-80% of 
prescribed medication (5, 6). Although any cut point for adherence is somewhat arbitrary there is 
some evidence of clinical effect when adherence falls below certain thresholds. For example, 
adherence of less than 60% has been found to be associated with significantly higher levels of 
healthcare utilisation (7). In an observational study, improvements across a range of asthma control 
measures during a period of electronic monitoring were seen in children with ≥80% adherence, but 
no improvements were seen in those whose monitored adherence was <60% (6).  
 
Nonadherence in paediatric asthma is a significant issue with reported adherence rates as low as 50% 
(8). Suboptimal adherence to ICS leads to poor asthma control, severe attacks of wheeze and 
hospitalisations(9). It is estimated that around 5-10% of asthmatic children have problematic severe 
asthma (asthma apparently not responding to maximal medications) and these children consume a 
disproportionate amount of NHS resources (10). Even among this group at least half of patients 
attending tertiary care paediatric clinics were found to be poorly adherent (11).  
 
There has been a call for change by several key asthma experts. The 2018 Lancet commission 
recommended that we “develop tests capable of identifying poor adherence and treatment 
approaches capable of improving adherence”(12). The UK national charity for asthma, Asthma UK, 
also highlighted the problem of nonadherence in their 2018 research priorities 
(https://www.asthma.org.uk/research/strategy/research-priorities/): “Regardless of how effective 
asthma treatments are, they will only work if people understand and appreciate their benefits and 
take them as prescribed… we know that a number of complex barriers exist which unnecessarily limit 
the level of control most people have over their asthma…” 
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The ERS/ATS Task Force on severe asthma recommend that nonadherence to treatment should 
be considered in all difficult to control patients before a label of “severe asthma” can be 
applied. However, the authors acknowledge that detecting poor adherence can be 
challenging (13).  Similarly, NRAD called for continual monitoring of adherence to ICS. 
 
To achieve these recommendations, we need reliable and affordable ways for healthcare 
professionals to assess adherence in children with problematic asthma.  There are a number of 
methods for monitoring adherence which will be reviewed. Some are subjective, while others utilise 
more objective measures. It is important that the correct tool is used to measure adherence in children 
with asthma. Each of the commonly used measurement tools have strengths and limitations which 
are summarised in this article alongside research which has used the tools either as an outcome 
measure or as part of an intervention. 
 
2. Adherence Monitoring Tools 
2.1 Subjective Monitoring Tools 
2.1.1 Physician Assessment of Adherence 
Physicians have consistently been shown to be unable to accurately identify which of their patients 
are not adhering to their asthma treatment. A recent study found that health care professionals were 
extremely poor at detecting nonadherence in their patients when assessing eligibility for advancement 
to novel biological therapies (14). Both specialist nurses and physicians were able to identify 
nonadherence in less than half of their patients when compared to objective measures. Adherence 
was significantly overestimated by nurses in 72% of cases and doctors in 85% of cases (14). 
 
 2.1.2 Parental and Child Assessment of Adherence 
Self and parental assessment is often used as a measure of adherence in research studies and in clinical 
practise as validated assessment tools are generally quick for patients to complete and are viewed as 
cost effective. However, self and parental reported adherence are often measured using non-
validated tools (15-18) . Whether or not a validated tool is used, adherence to ICS is frequently 
overestimated compared to objective measures (19). There can be a number of reasons for this 
including wanting to demonstrate behaviour (adherence) that is desired by the medical team. This 
issue can in some way be addressed by asking empathic questions that acknowledge the likelihood of 
poor adherence (20). 
 
2.1.2.1 Self-Report Questionnaires 
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Self-report questionnaires can be filled in by the parent or the child themselves depending on their 
development and validation.  The most frequently used questionnaires to measure adherence in 
asthma are the Morisky Scale (21) and the Medicines Adherence’s Report Scale - Asthma (MARS-A 
(22)).  
 
2.1.21.2 The Morisky Scale 
The Morisky scale was originally developed as a 4-item questionnaire for hypertension medication 
adherence with dichotomous yes/ no responses. The scale was found to have good concurrent and 
predictive validity for objective blood pressure readings at 2 and 5 years. More recently the scale was 
developed into a more predictive 8-item questionnaire with dichotomous answers except the final 
answer which was is a five-point Likert scale (23). The Morisky scale has been used in a variety of 
health conditions including asthma but it has not frequently been used to measure adherence in 
children with asthma. The studies that have used the Morisky Scale were conducted in mixed 
populations which included both children and adults (24-29).  In 2017 the Morisky scale was developed 
and validated for use in asthma as an 8 item questionnaire (Morisky Medication Adherence Scale, 
MMAS-8) (30) in patients over 12 years old. The questionnaire was tested in a Slovenian population 
and correlated well with asthma control and quality of life. However, it has not been validated using 
objective measures of adherence.  
 
2.1.2.1.3 The Medication Adherence Report Scale (MARS) 
The Medication Adherence Report Scale (MARS) was originally developed and validated in multiple 
disease populations including  asthma (31). The MARS consists of 9 items which are all scored on a 5-
point Likert scale and it has been adapted for the asthmatic population  specifically to address 
adherence to ICS. The MARS-A, a 10-item scale was validated in adult patients with asthma and has 
been found, in research studies, to be only moderately correlated with electronic monitoring data (r 
= 0.42, P = 0.001) (22). However, in children it is often the parents who complete the questionnaire 
on behalf of the child (32, 33) and both the MARS-A and MARS-5, a shortened version, have been 
found to be inaccurate in children when administered in clinical practice and compared to  EMD data  
(6, 34). 
 
 
 
 
2.2 Objective Monitoring tools  
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2.2.1 Prescription Data 
Prescription data is an objective measure which is often used as a proxy for adherence (36, 37). It 
describes how often the patient (or parent of a patient) is prescribed a prescription, usually for ICS or 
other maintenance therapy, and presented as a percentage of the expected number of prescriptions 
over a given time period (usually one year). Although objective, prescription data only give an 
indication of complete non-adherence; if no prescriptions are collected then no medication can be 
taken but collecting a prescription script is not the same as collecting the medication from the 
pharmacy or inhaling the medication. Prescription data are relatively easy to obtain, particularly by 
the primary care physician and this is often used clinically as a proxy for nonadherence.  
 
Prescription refill rate (PRR) describes the amount of medication actually collected from a pharmacy. 
Although this gives a little more information than simple prescription data  it also does not allow for 
the unknown factor of whether patients actually take the medication or just store them until they go 
out of date (38). Furthermore, in areas where prescriptions are free for children, parents may collect 
medications ostensibly for their child, but in reality, for another adult, to take advantage of the cost 
savings. Despite the limitations of PRR it can provide useful insights into medication use and is a 
popular adherence outcome for research studies targeting adherence and has been used in many 
intervention studies in children with asthma (37, 39, 40). Despite the limitations of PRR it can also 
provide useful information on salbutamol use. Collection of 12 of more salbutamol inhalers was 
highlighted as a risk factor for asthma death by NRAD (2). This equates to >6puffs per day, every day, 
indicative of very poor asthma control and suggestive of discordance between preventer and reliever 
use.  
 
2.2.2 Weighing Inhaler Canisters 
Inhaler canisters returned to the clinician/researcher can be weighed using a digital scale to calculate 
the number of doses used. This method is costly as it requires a digital scale to be accessible. Again 
assumptions that have to be made may be incorrect and the results misleading, particularly if the 
patient has engaged in dose dumping, where a patient actuates the inhaler multiple times to discharge 
the drug in an attempt to appear adherent,  just before bringing the inhalers back or if the inhaler has 
been used by someone else (41). Canister weight is used more frequently in trials than in the clinical 
setting and it has been used to measure adherence in an RCT in children with asthma prescribed ICS 
(42). Weicha et al. (42) used canister weight in comparison to self-report adherence from both 
children with asthma and their parents and found that the objective versus subjective measures were 
vastly different with the objective measures (canister weight and DOSER CT™ being lower than the 
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subjective measures). This objective measurement allows researchers and clinicians to calculate how 
much of the medication has been taken (actuated not necessarily inhaled) although it does not have 
a mechanism to adjust for dose dumping.  
 
2.2.3 Dose Counters 
Dose counters indicate to the patient how many doses remain in their inhaler. The counter decreases 
as doses are taken or the inhaler is actuated and is embedded in the inhaler device. Clinicians or 
researchers may use this as an indication of adherence as it is easily accessible. However, as with 
weighing inhaler canisters the dose counter can be manipulated by dose dumping as the investigator 
has no indication of when the doses were taken or even if they were inhaled. 
 
2.2.4 Directly Observed Therapy 
Directly observed therapy (DOT) had long been used for diseases such as tuberculosis to ensure 
compliance with the whole treatment course. It can also be utilised in asthma to ensure a child takes 
their inhalers regularly, usually observed by a member of school staff, local pharmacy or nursing team.  
A recent pilot study has utilised a mobile device platform for remote direct observation of inhaler use 
and technique (43). Children are filmed using their device and then the video is uploaded via an App 
and reviewed by a specialist asthma nurse to assess inhaler technique. Mobile directly observed 
therapy (MDOT) is more flexible and convenient for children and their families than standard DOT and 
also has the advantage that inhaler technique is observed by someone with appropriate expertise.  
However, failure to upload a video does not mean that a child has not used their inhaler and is 
therefore not a measure of adherence per se. Furthermore, it is time intensive for families and nursing 
staff and requires children and their carers to not only remember to take the inhaler but to film it as 
well. There are also issues around data security and confidentiality.  
 
2.2.5 Nurse Home Visits 
Nurse led home visits can provide useful insights into adherence and provide information to 
complement self-report and prescription data. At the time of a home visit the location of all prescribed 
medications can be checked including whether they are easily accessible and if medications are 
present, whether they are within their use by date. Stockpiling of medications demonstrates that 
although inhalers are collected they are not being taken (11). 
 
 
2.3 Electronic Monitoring Devices   
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Electronic Monitoring Devices (EMDs) for asthma inhalers have been the focus of adherence research 
over the last 15 years. With advancements in technology improving year on year several types of 
devices have been developed, all with differing capabilities and prices. The current gold standard for 
measuring adherence is the use of EMDS such as the Smartinhaler™ (44). These EMDs measure when 
and how often patients activate their inhaler but currently not whether they are inhaling correctly. 
EMDs also do not provide information on why patients are nonadherent and they are currently not 
affordable for all clinical care settings.  
 
2.3.1 DOSER CT™ 
One of the first electronic monitoring devices for metered dose inhalers was the DOSER CT™ (45). The 
DOSER CT™ can be used with MDIs to count the number of doses used within a day up to 30 days 
(based on battery life). The DOSER CT™ uses a microchip and displays the amount of doses taken on 
the screen although this is a simple sum of the doses taken as opposed to the time and date of each 
dose. The DOSER CT™ is the cheapest EMD for ICS as it uses older technology than some of the newer 
EMDs but its key downfall is its inability to adjust for potential dose dumping. The DOSER CT™ has 
been used in a recent randomised control trial intervention based in America in children with asthma 
(42). The trial assessed changes in adherence between patients in the control group compared to 
those in the intervention group (a web-based self-management website named BostonBreathes). As 
the study was underpowered it did not find a significant difference in the DOSER CT™ adherence 
scores between groups however a post hoc analysis looking at those with low baseline adherence did 
show a significant improvement in those randomised to the intervention group (19). 
 
2.3.2 SmartInhalers™ 
SmartInhaler™  (Adherium, New Zealand) are currently considered the gold standard in clinically 
available tools, for objectively and accurately recording adherence data in asthmatic patients (46). 
They are fitted to the child’s usual inhaler and contain a microchip which collects data on when and 
how often an inhaler is actuated. The calculation of adherence from this device is not affected by dose 
dumping as it records the exact time, day and number of doses actuated so that the 
clinician/researcher can see if dose dumping has occurred and disregard the over-use of medication 
(if it is not relevant to their research).  The device can be fitted to many different types of inhalers and 
is easy for patients to transfer the device to a new inhaler when a prescription is renewed. Newer 
versions of the Smartinhaler are Bluetooth enabled. Children or their parents can download an App 
enabling them to monitor their own adherence, or health professionals can utilise this functionality to 
remotely monitor adherence and intervene rather than waiting for the device to be returned to clinic. 
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Although this can be beneficial it raises a number of issues: the time and resources needed for clinical 
staff to regularly monitor adherence and contact families; establishing who is responsible for ensuring 
a child’s adherence; and maintaining engagement and trust with the family rather than featuring in 
their lives as a “Big Brother” presence (47).  
 
As well as monitoring adherence, a number of studies have investigated their utility as an adherence 
intervention (48, 49). This is certainly plausible: one would expect that children would be more likely 
to take their inhalers if they know they are being monitored and the reminder function on the 
Smartinhalers can help those whose poor adherence is due to forgetfulness and poor routine.  Three 
paediatric randomised controlled trials of EMDs, demonstrated impressive differences in monitored 
adherence between the control and intervention arms (30% versus 85%; 49% versus 70% and 57.9% 
versus 79% respectively) (48-50). Chan et al. (48) noted significant improvement in a secondary 
outcome, asthma control scores, in the intervention group during the six month monitoring period 
and Morton et al. (49) noted a significant difference in asthma exacerbations over a 12 month 
period. However, interestingly significant difference between groups were not found for the three 
studies’ primary outcomes (time off school, change in ACQ score and FEV1% predicted respectively 
(48-50). This may in part be due to the fact that Smartinhalers measure actuation and not inhalation. 
It is possible that those with good adherence were using their devices incorrectly or deliberately 
manipulating them. A recent study demonstrated that real adherence is far less that actuations 
counted (51). Furthermore, adherence remained suboptimal (<80%) in a significant proportion of 
those monitored, suggesting that monitoring alone is insufficient as a sustained intervention. None-
the-less, important insights can be gained from the use of these devices. One study demonstrated that 
a period of monitoring is essential in determining management in those with problematic severe 
asthma (poor control despite prescription of high dose asthma treatment) (6). The study identified 
four groups: those with genuine severe asthma i.e. persistent poor control despite monitored good 
adherence who are candidates for a step up in treatment including addition of expensive biologics; 
those with good adherence whose control improved during the monitoring period (likely as a result of 
improved adherence), they require support to maintain adherence; those with poor adherence but 
improved control who require an intervention to improve adherence but are likely over-treated; and 
those with poor adherence and poor control for whom an adherence intervention is needed. Analysis 
of the adherence patterns can also be used as the basis for an honest and open discussion about 
adherence and as the basis for planning an appropriate adherence intervention (52, 53). 
 
2.3.3 Propeller Health (previously named Asthmapolis Device) 
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The Propeller Health electronic monitoring device attaches to the top of a pMDI inhaler canister or on 
the side of a DPI Diskus™ (Accuhaler) and measures, through GPS, both the location and the time and 
date of each inhaler actuation. The adherence data from the device can be downloaded using a USB 
cable or Bluetooth to a specifically designed smartphone application. The battery is rechargeable and 
the patient can fit the device onto any repeat prescription of the same inhaler. Propeller Health, which 
is FDA approved, has been used to measure both short acting beta agonist (SABA) (54) and ICS (55). 
Propeller Health has recently been used to measure SABA use in a large RCT (56) however to date no 
RCT has been conducted in ICS use. SABA use is likely to be investigated more frequently in the future 
as in indicator as poor adherence to ICS as high SABA use often correlates with low ICS use and vice 
versa. Propeller health devices are currently expensive costing approximately $300 per device. 
 
2.3.4 Inhaler Compliance Assessment (INCA) device 
The Inhaler Compliance Assessment (INCA) device measures adherence by recording the time and 
date of the actuation but importantly also contains acoustic sensors which can detect inhalation (57, 
58). This has clear advantages over the currently commercially available Smartinhalers; however, it is 
only clinically available for the Diskus™ (Accuhaler) inhaler, a dry powder inhaler which is not suitable 
for younger children and has only been evaluated in adults. Current work is ongoing to make this 
technology adaptable to pMDIs for use in COPD and asthma within a clinical setting (59).    
Sulaiman et al. (60) have used the INCA to develop an algorithm to measure adherence over time (an 
area under the curve(AUC) measure),  which takes into account the time between doses as well as the 
inhaler technique, using acoustic sensors.  Measuring actuation alone significantly overestimates 
adherence. Furthermore, only the AUC method was significantly associated with positive changes in 
asthma quality of life, reliever use, and peak expiratory flow recordings over 3 months. 
The device has recently been tested in a randomised controlled trial in adults with severe uncontrolled 
asthma (58). Participants were randomised to an intensive education programme including inhaler 
technique or biofeedback based on data from the INCA device over a three-month period. Those in 
the biofeedback group had significantly higher actual adherence (both actuation and correct 
technique) in the third month of the intervention than the intensive education group (73% versus 63%; 
95% CI 2.8%-17.6%; p=0.02). Furthermore, the device enabled the identification of clinically 
meaningful groups, including those who remained “difficult to manage” (uncontrolled with poor 
adherence despite monitoring).    Similar groups were described previously in the Jochmann study; 
however, in that study the authors were unable to determine if those participants with poor control 
despite documented good adherence had poor inhaler technique or were refractory to treatment.  
This device certainly shows promise. Adapting this technology for other inhaler devices would enable 
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testing in a greater range of patient groups, including children. Further work is needed to see if a 
period of monitoring with biofeedback can lead to sustained improvements in inhaler technique. 
 
2.4 Integrating digital technologies 
 
The increasing use of technology to monitor adherence affords the opportunity to integrate 
monitoring with digital adherence interventions. As discussed above a number of EMD devices have 
utilised reminder functions built into the device (48, 49). However, an alarming device will only be 
effective if it is in close proximity to its user. A number of studies have looked at other ways of 
providing prompts.  The almost ubiquitous presence of a personal Smartphone suggests a much more 
effective conduit for delivery of reminders. Short messaging service (SMS) / text or phone messages 
have been shown to have a positive impact on adherence (61). Propeller health devices have also been 
used in conjunction with text message reminders with children with asthma. This pilot study is 
registered on clinicaltrails.org but has yet to publish results (ref: NCT02615743, (55)). Within the 
current literature objective measures of adherence are generally lacking in text message studies and 
there has been little impact demonstrated on clinical control. In one adolescent study only 37% of 
participants offered SMS medication reminders successfully adopted this feature (62). However, such 
interventions need to be tailored to the target population and text messages and telephone calls are 
not the standard means of communication for most young people. Newer versions of EMDs have an 
associated App enabling the reminder to be delivered via a mobile device. Such Apps also afford the 
user the opportunity to monitor their own adherence, providing support for directed self-
management.  Whether evidence of benefit can be demonstrated before technology has again moved 
on remains to be seen.  
 
2.5 Biomarkers of adherence 
2.5.1 Drug levels 
Measurement of theophylline levels is usually undertaken to ensure the dose is in the therapeutic 
range; however very low or undetectable levels measured in either serum or saliva indicate poor 
compliance (63). Interpretation of these levels depends on knowing when the drug was reported or 
scheduled to have been taken and are unreliable if taken more than 12 hours after administration of 
a slow release tablet or 2 hours after immediate release preparations. For those on maintenance oral 
steroids serum prednisolone levels can be measured (64). This assay is only valid if measured within 6 
hours of the dose. A suppressed random cortisol level would also be expected if prednisolone has 
been taken regularly. Prednisolone assays are available only in specialist centres and timing can be 
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difficult particularly for children prescribed alternate day prednisolone, who always seem to attend 
clinic on the day they are not scheduled to take the dose! Whilst drug levels can be useful, only a very 
small number of children are prescribed theophylline or maintenance prednisolone. It is possible to 
measure inhaled steroid metabolites in blood and urine (65), however at present these assays are 
generally only available in research settings or doping labs.  
 
2.4.2 Exhaled nitric oxide 
Fraction of exhaled nitric oxide (FENO) is an indirect measure of eosinophilic airway inflammation and 
usually falls in response to inhaled steroids. FENO at the end of a period of monitoring with an EMD 
was found to have the best correlation with adherence and a significant fall in FENO was observed in 
those with good (≥80%) and moderate (60-79%) adherence over the monitoring period (6). FENO 
suppression has been shown to be useful in identifying nonadherence in adult patient with difficult 
asthma (DA) both in the context of research and clinically. McNicholl et al. (66) explored this in patients 
with FENO of (>45ppb) and patients who collected 80% or more versus less than 50% of their ICS 
prescriptions. They found FENO suppression to be a useful objective measure after directly observed 
therapy to detect poor adherence in difficult asthma. FENO is increasingly available in clinical care and 
could be combined with either DOT or EMD monitoring to identify those with previous poor 
adherence. However, it may be less useful in children. In the Jochmann study (6) 35% of the paediatric 
cohort had FENO levels of <25ppb at enrolment and therefore FENO suppression cannot be used in 
these patients. Furthermore, FENO did not distinguish those with poor control and poor adherence 
and those with poor control and good adherence.  
 
The key features of monitoring tools are summarised in Table 1.  
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Table 1: Pros and Cons of the key adherence monitoring measurement tools 
Type of Tool Development 
Year 
Pros Cons Published data on 
reliability 
 
2.1  
Subjective 
 
2.1.2.1.2 
Morisky Scale  
MMAS- 1986 
MMAS-8- 2017 
 Short and easy to 
administer 
 Inexpensive 
 Originally developed in 
hypertension 
 Not used frequently in 
paediatric asthma 
research 
 Yes (21, 23) 
2.1.2.1.3 
 
Medicines 
Adherence 
Report Scale 
(MARS – A and 
MARS-5) 
 
MARS  
MARS-5- 2002 
MARS-A- 2009 
  
 Short and easy to 
administer 
 Inexpensive 
 Correlates to electronic 
monitor data in the adult 
validation study 
  
 Self-report generally 
over-estimates 
adherence in children 
in clinical settings 
 
 Yes (22) 
2.2  
Objective 
 
2.2.4 
Mobile Directly 
Observed 
Therapy 
2018  Inhaler technique can be 
checked in addition to 
adherence 
 MDOT reduces the travel 
burden for traditional 
DOT at the hospital or a 
community location 
 Patients may take 
their inhaler without 
uploading a video 
 Reviewing videos is 
time consuming for 
the clinicians 
(expensive) 
 Uploading the video 
relies on an internet 
connection 
 Yes (43) 
2.3 
Electronic Monitoring Devices 
 
2.3.1  
Doser CT™ 
1998  Most inexpensive of the 
electronic devices 
 Records the number of 
actuations 
 Does not record the 
time and date of each 
actuation- open to 
dose dumping 
 Memory is only 30 
days long 
 Yes (45) 
2.3.2 
SmartInhalers™ 
 
2006  Measures when and how 
often ICS is taken- avoids 
dose dumping 
 Can be put onto different 
types on inhalers by the 
patient/parent 
 It is commercially available   
 Can have a reminder alarm 
enabled 
 Expensive  
 Can be manipulated as 
actuation not 
inhalation measured 
 It does not measure 
inhalation 
 Bluetooth enabled 
 Yes (46) 
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 Rechargeable 
 Bluetooth enabled link to a 
mobile app 
2.3.3  
Propeller Health  
2018  GPS enabled 
 Measures when and how 
often ICS is taken- avoids 
dose dumping 
 It has a light which tells the 
user when in needs 
charging, when a dose is 
taken and when it is 
plugged into the USB cable 
 It is Bluetooth enabled and 
has its own app 
 The most expensive 
device  
 It is not currently 
available for routine 
clinical use Not 
commercially available 
for clinical use 
  
 It does not measure 
inhalation  
 Yes (54, 55) 
2.3.4 
Inhaler 
Compliance 
Assessment 
(INCA) 
2013  Measures how, when and 
how often a dose is taken- 
avoids dose dumping 
 Measures inhalation 
technique 
 Not commercially 
available for clinical 
use 
 Only available for DPIs 
(pMDI in development) 
 It is not Bluetooth 
enabled and does not 
have an accompanying 
app 
 Only validated in adults 
with an effect over a 
three month period 
 Yes (57, 58) 
 
 
3. Conclusion 
No single self-report adherence questionnaire has been developed and validated with children with 
asthma and therefore they have shown limited clinical use. Although other clinical tools such as 
prescription data can be a useful and low cost way to assessment tool they are likely to overestimate 
adherence. EMDs are currently seen as the gold standard for measurement of adherence in asthma. 
However, current EMDs have key limitations including the lack of measurement of inhalation and the 
high cost. The development of the next generation of EMDs which can assess inhalation and inhaler 
technique is exciting and to be welcomed.  
 
4. Expert commentary 
Optimising adherence to medications is a key challenge in asthma management.  Over the past 15 
years the development, and increasing use, of electronic monitoring devices have enabled a more 
accurate assessment of adherence – an essential starting point in identifying and improving poor 
adherence. However, these devices are not a panacea. They do not capture the patient’s “usual” 
adherence as the process of monitoring leads to improved adherence in many. Conversely, they do 
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not appear to be a sufficient intervention in themselves to lead to sustained improvements in asthma 
control: adherence decreases the longer the monitoring period and crucially, in all but the INCA device, 
they monitor actuation and not inhalation. None-the-less they can provide valuable data both for the 
patient and the healthcare provider. Firstly, asthma control can be interpreted in the context of known 
adherence; secondly the combination of adherence data and changes in asthma control during a 
period of monitoring can be used as the basis of a concordance interview and to identify an 
appropriate adherence intervention; and finally the reminder function and connectivity with an App 
which records usage may be helpful for some patients as a tool to improve adherence.  
 
The current costs and availability of EMDs limits their use and they are not part of mainstream care in 
most territories. Given the huge costs of asthma management it is possible that the use of these 
devices could lead to financial savings making them attractive to providers/ payers, and therefore a 
health economic analysis of their use would be most welcome. In the meantime, other forms of 
adherence monitoring such as prescription refill rate and empathic questioning have their role, 
provided the limitations, as discussed in this article, are recognised.  
 
The further development of novel digital platforms is a fast-moving field. EMDs which include a 
measure of inhalation (either utilising acoustic or flow sensors or video capture) offer greater potential 
to improve asthma control by addressing practical barriers (i.e. inhaler technique). Further studies are 
needed to assess whether they do offer benefit over currently available devices. There is a risk that 
the greater the functionality, the greater the cost and likelihood of device failure. Improving reliability 
and driving down costs of current devices may yield greater benefit on a population level whereas 
more sophisticated devices may have greater utility for the individual. The differential pace of 
technology development compared to clinical trials is a challenge for those working in this area and a 
balance must be struck between innovation and evidence of benefit. 
 
Recognising poor adherence is an important step in asthma management; however, it is of little use 
unless it leads to meaningful engagement with the patient. Knowing whether a patient is adherent or 
not does not uncover the myriad reasons for poor adherence nor does it automatically lead to 
improved adherence. Non-judgemental patient doctor communication based on objective 
adherence data is vital to target adherence behaviour effectively.  Combining EMDs with a 
simple questionnaire tool to profile adherence beliefs in individuals could help to identify key areas 
for discussion between patients and healthcare providers and to personalise adherence interventions.  
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The importance of adherence in asthma care is well established. Decreasing costs and improved 
usability of EMDs offers the prospect of adherence monitoring becoming part of mainstream care. It 
is possible that in the near future all inhalers could contain some sort of in-built monitoring device. 
The technological challenges are relatively easy to address; implementing behaviour change on the 
part of the patient and the healthcare provider is a mountain yet to be climbed.  
 
 
5. Five-year view 
We expect that within five years a range of electronic monitoring devices will be available for clinical 
use to measure both inhaler technique and medication adherence.  Using these devices at scale should 
lead to reduced costs enabling them to be part of mainstream asthma care. We hope that these 
devices are embraced and used by clinicians to better understand, discuss and influence adherence 
behaviour in people with asthma.  We envisage that they will become a key element of directed self-
management and will be integrated with other digital technologies to improve asthma monitoring.   
 
 Key issues  
 Self-report adherence questionnaires have not been utilised successfully in clinical 
studies in children although to date there are no questionnaires which have been 
developed for, and validated in paediatric populations  
 There are a number of objective measures which can be utilised, particularly in a 
specialist setting, including nurse-led home visits; biomarkers such as FENO 
suppression monitoring and prescription data but each have limitations 
 Within the last 15 years Electronic Monitoring Devices (EMDs) have been the focus for 
monitoring adherence, however each of these too have their limitations: availability 
of devices; cost; the ability of the patient to manipulate the data (i.e. by dose dumping 
or by actuating without inhaling); accuracy of inhaler technique is not always known; 
and EMDs are not available for all types of inhalers 
 Next generation EMDS include the ability to measure inhalation and potentially 
inhaler technique 
 At present there is little evidence to suggest that EMDs are a sustainable adherence 
intervention  
 Recognition of poor adherence is the starting point for non-judgmental discussions 
around inhaler use and the basis of identifying n appropriate intervention 
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